Work outside the body
An extracorporeal approach to selective cell separation.
One mission. Software and discovery.
End bone
marrow
cancer.
A future beyond bone marrow cancer, led by Software as a Medical Device (SaMD) and our stealth Drug Discovery Program. Cellular intelligence today. New therapeutic possibilities for the future.
AI-generated concept artwork
01 / The reason we exist
An extraordinary
mission demands
a different approach.
A future beyond bone marrow cancer.
That is the purpose behind NanoCure AI. Our future is centered on two programs: Software as a Medical Device (SaMD) and Drug Discovery.
Our leukemia models bring cell-level evidence into expert review. Our stealth Drug Discovery Program pursues new therapeutic possibilities through research partnerships.
An extracorporeal medical device remains part of our longer-term vision, alongside these two core programs.
One mission SaMD · Drug discovery · A future beyond cancer
02 / Software as a Medical Device (SaMD)
Cellular intelligence.
A core part of our future.
Our SaMD program puts expert-led image review at the center. The Leukemia Model program supports identifying malignant cells in AML, ALL, and CLL patients, with disease-specific development and evaluation guided by the roadmap below.
LEUKEMIA MODELS / CELL REVIEW
Leukemia Models App
Built around the
hematopathologist’s workflow.
From bone marrow and peripheral blood images to cell-level review, the application supports malignant-cell identification while keeping interpretation and adjudication with the hematopathologist.
- Bone marrow and peripheral blood morphology
- Cell-level evidence and expert adjudication
- Malignant-cell identification across the AML → ALL → CLL roadmap
Explore the app overview, then sign in to your workspace.
Leukemia model development · AML → ALL → CLL
Our leukemia models.
A focused path forward.
AML → ALL → CLL is the development roadmap for our leukemia models. Each expansion requires disease-specific evidence and expert evaluation.
Build the foundation
Start with AML morphology.
Make review traceable.
Our current emphasis is AML-focused morphology and malignant-cell review across bone marrow and peripheral blood images. Cell-level evidence and expert adjudication provide the basis for continued evaluation.
Current development & evaluationExpand the evidence
Extend to ALL.
Evaluate on its own terms.
The next expansion centers on malignant-cell identification in acute lymphoblastic leukemia. The program connects ALL-specific images and expert review to the broader foundation-model effort, with separate evaluation of disease-specific performance.
Research expansionBroaden the program
Build toward CLL.
Keep validation specific.
CLL is the next roadmap direction after AML and ALL, focused on malignant-cell identification. Broader morphology coverage will require representative data, expert-labeled evidence, and a clearly defined intended use before clinical claims can be made.
Future development directionThis roadmap describes development priorities, not regulatory clearance or clinical availability for every disease.
03 / Our future · Stealth research
Drug Discovery
Program.
New therapeutic possibilities.
The same mission.
NanoCure AI is advancing a stealth Drug Discovery Program to pursue new therapeutic possibilities for bone marrow cancer. Together with our SaMD program, this work is central to our long-term future.
We are building this program in partnership with Dr. Rai’s Cancer Hospital and Dr. Siddharth Rao Chelikani.
The program remains in stealth. Biological targets, mechanisms, and candidate details remain confidential while the research advances.
Drug Discovery Program · Stealth04 / Longer-term medical device program
Change the approach.
Outside the body.
Extracorporeal device · Longer-term development
Selective cell removal.
A longer-term engineering program.
Alongside our primary SaMD and Drug Discovery Programs, we’re developing an extracorporeal medical device to identify and selectively remove malignant cells from circulation. This is a separate, longer-term engineering effort.
Focus on malignant cells
Develop recognition and separation around cell-level evidence.
Pursue a drug-free approach
Non-toxic disease removal is the design goal guiding the work.
EXTRACORPOREAL SYSTEMConcept visualization · In development
A different path
through cancer.
Explore the idea behind selective cell separation outside the body.
Recognition before separation.
Our development approach begins with imaging and cell-level recognition, informing the future engineering of selective separation.
This is a development program. Non-toxic, drug-free cell removal is a design objective; safety and clinical benefit must be established through appropriate evaluation. The interactive scene illustrates the concept, not a validated device or patient outcome.
05 / Our founder
Julius Lamar
Original Founder · CEO & CTO
One mission.
A future beyond bone marrow cancer.
The reason I build
“NanoCure AI is more than an invention; it is my calling.”
I founded NanoCure AI to turn an engineering vision into meaningful progress against bone marrow cancer. Research, experimentation, and evidence guide how we build.
Our mission is to end bone marrow cancer. Software as a Medical Device and our stealth Drug Discovery Program lead our future: better cell-level evidence for experts and new therapeutic possibilities through research. Our extracorporeal device remains a longer-term part of that vision.
06 / The people advancing the mission
Co-founders &
medical advisors.
Bringing scientific, clinical, and engineering leadership to the work ahead.
Co-founders
Scientific, clinical, and technical leadership
Dr. Srividya BhaskaraPhD
Chief Scientific Officer
Dr. Jennifer BarkerMD
Chief of Hematopathology
Steven EllsworthDO
Lead Pathologist
Mahir Sukar
Lead Embedded Engineer
Medical advisors
Medical Advisory Board
Dr. Ashok SrivastavaMD, PhD, MBA
Medical Advisory Board
Dr. Mahesh ChandrasekharanPhD, MS
Medical Advisory Board
Dr. Himil ParikhMD
Medical Advisory Board
Dr. Siddharth Rao Chelikani
Medical Advisory Board
Build what comes next with us
Help move the
mission forward.
For researchers, clinical teams, engineers, and strategic partners who share our mission to end bone marrow cancer.
info@nanocureai.orgWebsite privacy
This notice covers the NanoCure AI company page. The page does not include advertising trackers or third-party analytics scripts. The company page and application share this website; the application uses session cookies for sign-in and access controls.
Browsing and contacting us
Hosting and network services may record technical information such as IP addresses, requested pages, request times, and response status for site operation, troubleshooting, and security. Authenticated application activity may also be recorded for access management and usage statistics.
Email links open your email application. Information you send is used to respond to your inquiry and continue the conversation. Please arrange any clinical-data exchange through an agreed channel.
The review platform
The application is available through App home on this website. Its authenticated workflows have their own access requirements and data-handling arrangements. External services, including LinkedIn and your email provider, have their own privacy practices.
For questions or requests about information you have shared with us, email info@nanocureai.org.
Updated September 16, 2026
Accessibility
We want people to explore NanoCure AI using the tools that work for them.
Using this website
The page includes a skip link, descriptive headings, image descriptions, visible keyboard focus, and a layout designed for smaller screens. The AML, ALL, and CLL roadmap supports arrow keys, Home, and End. A motion control pauses the ambient graphics. Motion follows your device’s reduced-motion preference.
Feedback and assistance
If a page or control is difficult to use, email info@nanocureai.org. Tell us which feature caused difficulty and, if you wish, the browser or assistive technology you used. You can request the information in another format.
This statement covers the public website. The review platform and external services are separate interfaces. An independent accessibility audit has not been completed.
Updated October 3, 2026